DE2655691C2 - Temperaturempfindliche, vermehrungsfähige, nicht pathogene Varicella-Zoster-Viren, Verfahren zu ihrer Herstellung und diese Viren enthaltende Lebendvaccine - Google Patents
Temperaturempfindliche, vermehrungsfähige, nicht pathogene Varicella-Zoster-Viren, Verfahren zu ihrer Herstellung und diese Viren enthaltende LebendvaccineInfo
- Publication number
- DE2655691C2 DE2655691C2 DE2655691A DE2655691A DE2655691C2 DE 2655691 C2 DE2655691 C2 DE 2655691C2 DE 2655691 A DE2655691 A DE 2655691A DE 2655691 A DE2655691 A DE 2655691A DE 2655691 C2 DE2655691 C2 DE 2655691C2
- Authority
- DE
- Germany
- Prior art keywords
- temperature
- virus
- sensitive
- pathogenic
- viruses
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 241000700605 Viruses Species 0.000 title claims description 49
- 229960005486 vaccine Drugs 0.000 title claims description 22
- 241000701085 Human alphaherpesvirus 3 Species 0.000 title claims description 14
- 230000001717 pathogenic effect Effects 0.000 title claims description 13
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- 238000000034 method Methods 0.000 title claims description 9
- 230000001850 reproductive effect Effects 0.000 title claims description 6
- 208000007514 Herpes zoster Diseases 0.000 claims description 13
- 238000004113 cell culture Methods 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 230000010076 replication Effects 0.000 claims description 5
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 2
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 claims 2
- 238000003306 harvesting Methods 0.000 claims 1
- 238000011081 inoculation Methods 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 3
- 201000006082 Chickenpox Diseases 0.000 description 2
- 206010046980 Varicella Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 231100000219 mutagenic Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940124863 Varicella-zoster virus vaccine Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000002226 anterior horn cell Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960001201 live attenuated varicella Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16761—Methods of inactivation or attenuation
- C12N2710/16763—Methods of inactivation or attenuation by chemical treatment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/821—Drug, bio-affecting and body treating compositions involving temperature-sensitive mutant virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/644,787 US4008317A (en) | 1975-12-29 | 1975-12-29 | Varicella-zoster virus vaccine and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2655691A1 DE2655691A1 (de) | 1977-07-14 |
| DE2655691C2 true DE2655691C2 (de) | 1985-08-14 |
Family
ID=24586321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2655691A Expired DE2655691C2 (de) | 1975-12-29 | 1976-12-08 | Temperaturempfindliche, vermehrungsfähige, nicht pathogene Varicella-Zoster-Viren, Verfahren zu ihrer Herstellung und diese Viren enthaltende Lebendvaccine |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4008317A (OSRAM) |
| JP (1) | JPS5282721A (OSRAM) |
| BE (1) | BE849897A (OSRAM) |
| DE (1) | DE2655691C2 (OSRAM) |
| FR (1) | FR2336944A1 (OSRAM) |
| GB (1) | GB1565830A (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0043847A4 (en) * | 1980-01-25 | 1982-07-06 | Wistar Inst | HIGHLY ATTENUED CHICKENPOX VIRUS VACCINE AND PRODUCTION THEREOF. |
| US4315914A (en) * | 1980-04-04 | 1982-02-16 | Seiji Arakawa | Pharmaceutical compositions useful as cellular immunopotentiator and antitumor agent and process for production thereof |
| US4714678A (en) * | 1982-10-13 | 1987-12-22 | Smithkline-Rit | Temperature sensitive strain of bovine viral diarrhoea virus |
| IT1213254B (it) * | 1984-12-06 | 1989-12-14 | Boehringer Biochemia Srl | Metodo diagnostico per la valutazione di parametri clinici mediante prelievo diretto dimateriali biologici e dispositivoper la sua attuazione. |
| ES2150906T3 (es) | 1990-10-04 | 2000-12-16 | Res Corp Technologies Inc | Antigeno del virus varicella-zoster. |
| US5824319A (en) * | 1990-10-04 | 1998-10-20 | Research Corporation Technologies, Inc. | Varicella-zoster virus antigen |
| JP4562812B2 (ja) * | 1992-07-17 | 2010-10-13 | メルク・シャープ・エンド・ドーム・コーポレイション | 帯状疱疹の予防または水痘関連ヘルペス後神経痛の緩和方法 |
| US5879675A (en) * | 1994-03-15 | 1999-03-09 | Medical College Of Pennsylvania And Hahnemann University | Compositions and methods for vaccines comprising α-galactosyl epitopes |
| US7666082B2 (en) * | 2004-05-07 | 2010-02-23 | Gamelogic Inc. | Method and apparatus for conducting a game of chance |
| US10350289B2 (en) | 2013-09-05 | 2019-07-16 | Merck Sharp & Dohme Corp. | Methods of immunization with varicella zoster virus antigen |
-
1975
- 1975-12-29 US US05/644,787 patent/US4008317A/en not_active Expired - Lifetime
-
1976
- 1976-12-08 DE DE2655691A patent/DE2655691C2/de not_active Expired
- 1976-12-22 GB GB53537/76A patent/GB1565830A/en not_active Expired
- 1976-12-24 JP JP15733876A patent/JPS5282721A/ja active Granted
- 1976-12-28 BE BE173669A patent/BE849897A/xx not_active IP Right Cessation
- 1976-12-29 FR FR7639469A patent/FR2336944A1/fr active Granted
Non-Patent Citations (1)
| Title |
|---|
| NICHTS-ERMITTELT |
Also Published As
| Publication number | Publication date |
|---|---|
| US4008317A (en) | 1977-02-15 |
| JPS5282721A (en) | 1977-07-11 |
| GB1565830A (en) | 1980-04-23 |
| FR2336944B1 (OSRAM) | 1980-07-18 |
| FR2336944A1 (fr) | 1977-07-29 |
| BE849897A (fr) | 1977-06-28 |
| JPS624370B2 (OSRAM) | 1987-01-30 |
| DE2655691A1 (de) | 1977-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69327307T2 (de) | Herstellung von antigenen und impfstoffen vom mysterie-disease-virus, antigene und erworbene impfstoffe zur verhinderung dieser krankheit | |
| DE2655691C2 (de) | Temperaturempfindliche, vermehrungsfähige, nicht pathogene Varicella-Zoster-Viren, Verfahren zu ihrer Herstellung und diese Viren enthaltende Lebendvaccine | |
| DE2516274C2 (de) | Verfahren zum Herstellen eines abgeschwächten Zytomegalie-Virus-Impfstoffes | |
| DE2610540C2 (de) | Verwendung eines OEP als Wirkstoff enthaltenden injizierbaren Impfstoffes zur Vorbeugung gegen die durch Pseudomonas aeruginosa hervorgerufene Pneumonitis der Nerze | |
| DE2817891A1 (de) | Nd-impfstoff und verfahren zu seiner herstellung | |
| DE3110801A1 (de) | Lebendes vakzin fuer die impfung von gefluegel und saeugetieren | |
| DE2463143C2 (de) | Polyvalente Rindervirus-Lebendimpfstoffe | |
| DE2445819A1 (de) | Verfahren zur herstellung stabiler, gegen seruminhibitoren resistenter h tief 3 n tief 2 -influenzavirusstaemme und diese virusstaemme enthaltende vakzinen | |
| DE2553998C2 (de) | Mumpsvaccin und Verfahren zu seiner Herstellung | |
| DE2415353C2 (OSRAM) | ||
| DE69328341T2 (de) | Impfstoff gegen infektiöse Bursal-Krankheit | |
| DE2425997A1 (de) | Verfahren zur herstellung von abgeschwaechtem katzenfiebervakzin | |
| DE3122669A1 (de) | "verfahren zur herstellung von neuen mutanten von herpes simplex-viren typ 1 und typ 2" | |
| DE2456636A1 (de) | Influenza-vakzine und verfahren zu ihrer herstellung | |
| DE2212277B2 (de) | Verfahren zur Herstellung einer Totvaccine gegen infektiöse atrophische Rhinitis der Schweine | |
| CH423095A (de) | Verfahren zur Herstellung eines Tollwutimpfstoffes | |
| DE2225548C3 (de) | Intravenös verträglicher Impfstoff gegen Staupe- und Hepatite contagiosa canis | |
| DE2737060C2 (de) | Escherichia coli-Neurotoxin | |
| DE2610426C2 (de) | Verwendung eines OEP als Wirkstoff enthaltenden Impfstoffes zur Bekämpfung der durch Pseudomonas aeruginosa hervorgerufenen Pneumonitis der Nerze | |
| DE1792256B2 (de) | Oral applizierbare, polyvalente Impfstoffe gegen lokale Darminfektionen | |
| WO1989005154A1 (fr) | Procede pour la preparation d'un virus avirulent pour animaux a sang froid | |
| DE3740182C2 (de) | Verfahren zur Herstellung eines Mutantenstamms von Bordetella bronchiseptica, der für einen Impfstoff für den Schutz von B. bronchiseptica-Infektionen nützlich ist, und daraus hergestellter AR-Impfstoff | |
| DE2440926C3 (de) | Injizierbarer inaktivierter Impfstoff gegen Hepatitis B und Verfahren zu seiner Herstellung | |
| DE2437166C3 (de) | Arzneimittel gegen interferonsensible, viralbedingte Infektionskrankheiten | |
| DE2128626C3 (OSRAM) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OGA | New person/name/address of the applicant | ||
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |